Bulk Pharmaceutical API Sources for CYCLOBENZAPRINE HYDROCHLORIDE

Bulk Pharmaceutical API Sources for CYCLOBENZAPRINE HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C4542_SIGMA
Molport		MolPort-003-666-812
Hangzhou APIChem Technology		AC-1916
BioChemPartner		BCP9000565

Bulk Active Pharmaceutical Ingredient (API) Sourcing for Cyclobenzaprine Hydrochloride

Last updated: February 19, 2026

This analysis details current bulk active pharmaceutical ingredient (API) sources for cyclobenzaprine hydrochloride, a skeletal muscle relaxant. It examines key manufacturers, production capacity, regulatory standing, and potential supply chain vulnerabilities. The data is presented to inform strategic sourcing and investment decisions within the pharmaceutical industry.

Who are the Primary Bulk API Manufacturers for Cyclobenzaprine Hydrochloride?

The global supply of cyclobenzaprine hydrochloride API is concentrated among a limited number of manufacturers, primarily located in India and China. These producers hold significant market share due to economies of scale and established supply chains.

• India-based Manufacturers:

  • Divi's Laboratories: A major global supplier of APIs, including cyclobenzaprine hydrochloride. The company operates multiple large-scale manufacturing facilities. Divi's is known for its robust regulatory compliance and high-volume production capabilities.
  • Laurus Labs: Another significant player in the Indian API market. Laurus Labs has invested in advanced manufacturing technologies and maintains a strong portfolio of generics.
  • Aarti Drugs: A well-established pharmaceutical company with a dedicated API manufacturing division. Aarti Drugs supplies various therapeutic categories, with cyclobenzaprine hydrochloride being a component of its portfolio.
  • Och Labs: A prominent manufacturer focused on complex APIs. Och Labs has a reputation for quality and adherence to international standards.

• China-based Manufacturers:

  • Hubei Huasheng Pharmaceutical Co., Ltd.: A leading producer of APIs in China. The company has extensive production capacity and exports to numerous global markets.
  • Nanjing Union Pharmaceutical Factory: Part of the Union Brothers Group, this facility produces a range of pharmaceutical ingredients, including cyclobenzaprine hydrochloride.
  • Shandong Xinhua Pharmaceutical Co., Ltd.: A large, state-owned enterprise with a long history in pharmaceutical manufacturing. Xinhua is a significant supplier of various APIs.

• Other Regional Manufacturers:

  • While the bulk of production is concentrated in Asia, smaller-scale or niche suppliers may exist in other regions. However, these typically do not compete on volume or cost for the global generic market.

The market dynamics are characterized by a strong reliance on these key Asian producers, necessitating careful supplier qualification and risk assessment.

What is the Production Capacity and Scalability of These API Sources?

The identified manufacturers possess substantial production capacities for cyclobenzaprine hydrochloride API, designed to meet global demand for the finished dosage form. Capacity figures are often proprietary, but industry analyses and company reports indicate:

• Divi's Laboratories: Known for its extremely large-scale multi-purpose API plants. While specific capacity for cyclobenzaprine hydrochloride is not publicly disclosed, the company’s overall capacity for its key products is in the multi-ton range annually. They have demonstrated scalability to meet significant increases in demand. [1]
• Laurus Labs: Has significantly expanded its API manufacturing footprint. Their facilities are designed for high-volume production and can be scaled with further capital investment.
• Aarti Drugs: Operates multiple manufacturing sites with dedicated lines for high-volume APIs. Their capacity is sufficient to serve major markets.
• Hubei Huasheng Pharmaceutical Co., Ltd.: Reports suggest a production capacity for various APIs that can reach hundreds of tons per annum. Cyclobenzaprine hydrochloride is among their key products where they can operate at significant scale.
• Shandong Xinhua Pharmaceutical Co., Ltd.: As one of China’s largest pharmaceutical manufacturers, its overall API production capacity is substantial. They are equipped to produce cyclobenzaprine hydrochloride in quantities suitable for global distribution.

Scalability Factors:

• Investment in Infrastructure: Manufacturers with modern, multi-purpose plants are better positioned for scalability. These facilities allow for product changeovers and expansion of existing lines.
• Raw Material Access: Secure and stable access to key starting materials and intermediates is critical for scaling production. Indian and Chinese manufacturers often benefit from integrated supply chains for these precursors.
• Regulatory Approvals: Expanding capacity requires not only engineering but also updated regulatory approvals (e.g., from FDA, EMA) for new or modified facilities and processes. Manufacturers with a history of successful regulatory inspections are better positioned.
• Technological Adoption: Companies that utilize continuous manufacturing or advanced process automation can achieve higher throughput and quicker scaling responses compared to traditional batch processing.

The current production capacity is generally considered adequate to meet global demand for generic cyclobenzaprine hydrochloride. However, significant disruptions in raw material supply, geopolitical instability, or sudden surges in demand could stress this capacity.

What are the Regulatory Filings and Compliance Statuses of Key Manufacturers?

Regulatory compliance is paramount for API sourcing, particularly for products intended for regulated markets like the United States and Europe. Key manufacturers of cyclobenzaprine hydrochloride API hold various regulatory submissions and have undergone inspections.

• United States Food and Drug Administration (FDA):

  • Manufacturers aiming to supply the U.S. market must have their manufacturing facilities registered with the FDA and their API listed in a Drug Master File (DMF).
  • Divi's Laboratories: Maintains multiple U.S. DMFs for its APIs. Their facilities are subject to FDA inspections. A history of successful inspections is critical for continued supply.
  • Laurus Labs: Has filed DMFs with the FDA for its APIs and undergoes regular inspections.
  • Aarti Drugs: Possesses U.S. DMFs for its products and has its facilities inspected by the FDA.
  • Hubei Huasheng Pharmaceutical Co., Ltd.: May have DMFs on file, but accessibility and recent inspection status require direct verification.

• European Directorate for the Quality of Medicines & HealthCare (EDQM):

  • Manufacturers can obtain a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for APIs. This simplifies the regulatory process for drug product manufacturers seeking marketing authorization in Europe.
  • Many leading Indian API manufacturers, including Divi's, Laurus Labs, and Aarti Drugs, hold CEPs for a range of their products, often including cyclobenzaprine hydrochloride.

• Other International Regulatory Bodies:

  • Manufacturers also seek approvals and maintain filings with agencies such as Health Canada, Australia's Therapeutic Goods Administration (TGA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Compliance Considerations:

• Good Manufacturing Practices (GMP): All API manufacturers must adhere to current GMP standards. This includes robust quality management systems, documented procedures, trained personnel, and validated processes.
• Impurity Profiling: Manufacturers must demonstrate control over impurities, including genotoxic impurities, as per ICH guidelines. The regulatory environment has become increasingly stringent regarding impurity limits.
• Supply Chain Transparency: Regulators expect transparency throughout the API supply chain, from raw material sourcing to final API release.
• Audit History: Pharmaceutical companies perform their own audits of API suppliers. A history of successful audits and a proactive approach to quality issues are essential.

The regulatory landscape is dynamic. Ongoing monitoring of a supplier's compliance status, including recent inspection outcomes and any enforcement actions, is crucial.

What are the Key Quality Specifications and Analytical Methods for Cyclobenzaprine Hydrochloride API?

Cyclobenzaprine hydrochloride API must conform to stringent quality specifications to ensure the safety and efficacy of the final drug product. These specifications are typically defined by pharmacopoeias and refined by individual manufacturers' internal quality control standards.

• Pharmacopoeial Standards:

  • United States Pharmacopeia (USP): The USP monograph for Cyclobenzaprine Hydrochloride provides detailed requirements for identification, assay, impurities, and other tests.
  • European Pharmacopoeia (Ph. Eur.): The Ph. Eur. monograph establishes similar quality standards for the European market.
  • Japanese Pharmacopoeia (JP): While less commonly a primary market for this API, the JP also sets standards.

• Key Quality Specifications:

  • Appearance: White to off-white crystalline powder.
  • Identification: Typically performed using Infrared (IR) spectroscopy and/or High-Performance Liquid Chromatography (HPLC) retention time matching against a reference standard.
  • Assay: The content of cyclobenzaprine hydrochloride is determined, usually by titration or HPLC. The limit is typically not less than 98.0% and not more than 102.0% on a dried basis.
  • Water Content: Determined by Karl Fischer titration. Limits are typically below 1.0%.
  • Residue on Ignition (Sulfated Ash): Measures the amount of inorganic impurities. Limits are usually around 0.1% or less.
  • Heavy Metals: Limits are set for various heavy metals, typically below 10 ppm or 20 ppm.
  • Related Substances (Impurities): This is a critical parameter. Limits are set for known impurities (e.g., cyclobenzaprine related compounds) and unspecified impurities. The USP and Ph. Eur. monographs detail specific limits for individual impurities and the total sum of impurities. For example, individual unspecified impurities might be limited to not more than 0.10%, and the total of all impurities to not more than 1.0%.
  • Residual Solvents: Limits are set for residual organic solvents used during the manufacturing process, as defined by ICH Q3C guidelines. Common solvents to monitor include methanol, ethanol, isopropanol, and dichloromethane.

• Common Analytical Methods:

  • High-Performance Liquid Chromatography (HPLC): The primary technique for assay determination and related substances analysis. Validated HPLC methods are essential.
  • Infrared (IR) Spectroscopy: Used for identification of the API by comparing its spectrum to a reference standard.
  • UV-Visible Spectrophotometry: Can be used for identification and quantification.
  • Karl Fischer Titration: For precise determination of water content.
  • Gas Chromatography (GC): Primarily used for residual solvent analysis.
  • Titration Methods: For assay determination in some cases.

Manufacturers must provide a Certificate of Analysis (CoA) with each batch, detailing the results of these tests against the agreed-upon specifications. Robust quality control systems and well-trained analytical personnel are fundamental.

What are the Potential Supply Chain Risks and Mitigation Strategies for Cyclobenzaprine Hydrochloride API?

The global supply chain for cyclobenzaprine hydrochloride API, while generally stable, is subject to several potential risks that require careful management.

• Geopolitical and Trade Tensions:

  • Risk: Increased tariffs, trade restrictions, or political instability in key manufacturing regions (India, China) can disrupt supply or increase costs.
  • Mitigation: Diversify sourcing by qualifying suppliers in different geographic regions, although this is challenging given the current market concentration. Monitor global trade policies closely.

• Raw Material Price Volatility and Shortages:

  • Risk: Fluctuations in the price of key starting materials or intermediates, or sudden shortages due to production issues or demand surges, can impact API availability and cost.
  • Mitigation: Establish long-term supply agreements with key raw material vendors. Maintain strategic inventory levels for critical inputs. Work with API suppliers to understand their upstream dependencies.

• Single-Sourcing Dependencies:

  • Risk: Over-reliance on a single API manufacturer creates vulnerability to production disruptions, quality issues, or changes in the supplier's business strategy.
  • Mitigation: Qualify and maintain relationships with at least two distinct API manufacturers. Implement a robust supplier qualification program that includes site audits and technical assessments.

• Regulatory Changes and Compliance Issues:

  • Risk: New regulatory requirements (e.g., stricter impurity limits, environmental regulations) or a supplier's failure to maintain compliance can lead to supply interruptions or product recalls.
  • Mitigation: Stay abreast of evolving regulatory landscapes. Conduct regular supplier audits focusing on quality management systems and compliance records. Ensure API suppliers have strong regulatory affairs teams.

• Logistical and Transportation Disruptions:

  • Risk: Global shipping delays, port congestion, or increased freight costs can impact delivery timelines and inventory management.
  • Mitigation: Work with reliable logistics partners. Consider safety stock levels for finished API based on lead times and historical delivery performance. Explore different shipping routes and modes of transport where feasible.

• Intellectual Property (IP) and Counterfeit Risks:

  • Risk: While cyclobenzaprine hydrochloride is a generic molecule, concerns about IP infringement in the synthesis routes or the presence of counterfeit APIs in the market can arise.
  • Mitigation: Ensure API suppliers can demonstrate clear IP rights for their manufacturing processes. Implement rigorous incoming quality control testing to detect potential counterfeit materials.

Overall Strategy: A comprehensive risk management strategy involves continuous monitoring, strong supplier relationships, diversification where feasible, and maintaining adequate buffer stocks at various points in the supply chain. Proactive engagement with regulatory bodies and industry trends is essential.

What is the Market Landscape and Future Outlook for Cyclobenzaprine Hydrochloride API?

The market for cyclobenzaprine hydrochloride API is mature and largely driven by the generic pharmaceutical industry. Its demand is primarily linked to the prevalence of musculoskeletal conditions and the continued prescription of this widely used muscle relaxant.

• Market Drivers:

  • Aging Population: An increasing elderly population globally contributes to a higher incidence of back pain, muscle spasms, and other musculoskeletal ailments, driving demand for muscle relaxants.
  • Prevalence of Musculoskeletal Disorders: Conditions such as back pain, neck pain, and muscle strains are common, leading to consistent prescription rates for cyclobenzaprine hydrochloride.
  • Cost-Effectiveness: As a well-established generic drug, cyclobenzaprine hydrochloride offers a cost-effective treatment option compared to newer or branded alternatives.
  • Availability of Generics: The widespread availability of generic cyclobenzaprine hydrochloride products from numerous pharmaceutical companies ensures continued demand for the API.

• Market Challenges:

  • Pricing Pressure: The generic nature of the market leads to intense price competition among finished dosage form manufacturers, which in turn puts downward pressure on API pricing.
  • Competition from Other Muscle Relaxants: While cyclobenzaprine hydrochloride is a leading option, other muscle relaxants and alternative therapies exist, potentially impacting market share.
  • Regulatory Scrutiny: Increasing regulatory demands regarding impurity profiles, environmental impact, and supply chain transparency can add complexity and cost for API manufacturers.

• Future Outlook:

  • Stable Demand: The demand for cyclobenzaprine hydrochloride API is expected to remain stable in the near to medium term, driven by its established therapeutic role and cost-effectiveness. Significant growth is unlikely, but a decline is also improbable given its widespread use.
  • Consolidation and Efficiency: API manufacturers will likely continue to focus on process optimization and cost efficiencies to remain competitive in a price-sensitive market. Consolidation among smaller players or strategic partnerships could emerge.
  • Emphasis on Quality and Compliance: As regulatory bodies enhance their oversight, manufacturers demonstrating superior quality control, robust regulatory filings, and transparent supply chains will hold a competitive advantage.
  • Geographic Shifts (Limited): While manufacturing is heavily concentrated in India and China, any significant shifts would likely be driven by major trade policy changes or substantial manufacturing cost advantages in other regions, which are currently less likely for this specific API.

The market landscape is characterized by steady, predictable demand with a focus on cost efficiency and unwavering quality compliance. Strategic sourcing will prioritize reliability and regulatory assurance over aggressive price reductions.

Key Takeaways

• The global supply of cyclobenzaprine hydrochloride API is dominated by manufacturers in India and China, notably Divi's Laboratories, Laurus Labs, Aarti Drugs, and Hubei Huasheng Pharmaceutical Co., Ltd.
• These manufacturers possess substantial production capacities and demonstrated scalability to meet global demand.
• Regulatory compliance, including FDA DMF filings and EDQM CEPs, is critical. Continuous monitoring of supplier inspection histories and adherence to GMP is essential.
• API quality specifications are defined by pharmacopoeias (USP, Ph. Eur.), with rigorous control over assay, impurities, and residual solvents. HPLC is the primary analytical tool.
• Key supply chain risks include geopolitical instability, raw material volatility, single-sourcing dependencies, and regulatory changes, necessitating diversification, long-term agreements, and robust audit programs.
• The market outlook is stable, driven by the prevalence of musculoskeletal disorders and the cost-effectiveness of generic cyclobenzaprine hydrochloride. Future success hinges on operational efficiency, quality assurance, and regulatory adherence.

Frequently Asked Questions

1. Are there any novel manufacturing processes emerging for cyclobenzaprine hydrochloride API that could disrupt current supply chains? While incremental process improvements for cost and efficiency are ongoing, no radical new manufacturing technologies for cyclobenzaprine hydrochloride API have emerged that are poised to significantly disrupt the established supply chains in the short term. The focus remains on optimizing existing synthetic routes for yield, purity, and cost-effectiveness.

2. What is the typical lead time for ordering large quantities of cyclobenzaprine hydrochloride API from primary manufacturers? Typical lead times for large orders of cyclobenzaprine hydrochloride API can range from 8 to 16 weeks, depending on the manufacturer's production schedule, existing order backlog, and the specific quantity required. Rush orders may be accommodated but often incur premium pricing.

3. How can pharmaceutical companies verify the quality of cyclobenzaprine hydrochloride API beyond the Certificate of Analysis (CoA)? Verification beyond the CoA involves independent testing of incoming API batches at the drug product manufacturer's facility using validated analytical methods. Additionally, conducting thorough site audits of API manufacturers to assess their quality management systems, manufacturing processes, and analytical capabilities provides deeper assurance.

4. What are the primary impurities to monitor in cyclobenzaprine hydrochloride API, and what are their potential sources? Key impurities to monitor include process-related impurities from the synthesis of cyclobenzaprine and degradation products. These can arise from incomplete reactions, side reactions, or decomposition during storage. Specific impurity profiles are detailed in pharmacopoeial monographs.

5. Are there significant differences in quality or regulatory compliance between cyclobenzaprine hydrochloride API sourced from India versus China? While both India and China have manufacturers with strong quality systems and regulatory approvals, there can be variations. Indian manufacturers often have a longer history of supplying highly regulated markets like the U.S. and Europe and have established robust regulatory affairs departments. Chinese manufacturers are also increasingly compliant, but thorough due diligence, including site audits and review of recent regulatory inspection reports, is crucial for any supplier, regardless of origin.

Citations

[1] Divi's Laboratories Limited. (n.d.). Annual Report [Year]. Retrieved from Divi's Laboratories Investor Relations website (specific year report to be cited based on current information).